StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Protara Therapeutics's price to sales ratio was 67.3× on Apr 30, 2015.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2015Apr 30, 201567.3×–

More Protara Therapeutics figures

See a number that looks wrong?